Breaking News
June 17, 2018 - Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
June 17, 2018 - Bid to beat obesity focuses on fat that keeps us warm
June 17, 2018 - Work Stress May Increase Risk of Developing Atrial Fibrillation
June 17, 2018 - New Zealand’s secret recipe for active school travel: The neighborhood built environment
June 17, 2018 - New Medscape report reveals sexual harassment rate of physicians
June 17, 2018 - Surgical Blood Transfusions Tied to Clot Risk
June 17, 2018 - CDC chief makes $375K, far exceeding his predecessors’ pay
June 17, 2018 - Education linked to higher risk of short-sightedness
June 17, 2018 - Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial
June 17, 2018 - UA registers a more customised multifocal lens to correct presbyopia
June 17, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
June 17, 2018 - Vaginal estrogen tablets, moisturizers and placebo gel all can improve vaginal discomfort
June 17, 2018 - Addition of Bezafibrate Beneficial in Primary Biliary Cholangitis
June 17, 2018 - Radiation Therapy for Cancer – National Cancer Institute
June 17, 2018 - Technology could help pregnant women detect health complications
June 17, 2018 - Study finds drop in frequent use of ED after Affordable Care Act
June 17, 2018 - Do Antipsychotic Meds for Kids Raise Diabetes Risk?
June 17, 2018 - New light shed on mechanisms of paediatric epilepsy
June 17, 2018 - People who deeply grasp the pain or happiness of others also process music differently in the brain
June 16, 2018 - Scientists discover how cancer-targeting ‘Natural Killer’ cells are fueled in the body
June 16, 2018 - New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma
June 16, 2018 - Annual Report to the Nation: overall cancer mortality continues to decline, prostate cancer mortality has stabilized
June 16, 2018 - Ibuprofen, acetaminophen more effective than opioids in treating dental pain
June 16, 2018 - Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia
June 16, 2018 - Price competition for generic drugs linked to increase in manufacturing-related recalls
June 16, 2018 - Researchers develop biomimetic nanosystem to deliver therapeutic proteins to target tumors
June 16, 2018 - Negative Pressure Wound Tx No Benefit for Lower Limb Open Fx
June 16, 2018 - Should I Get Screened for Prostate Cancer?
June 16, 2018 - Biochemist, physicist team to see antibacterial TCS deform mitochondria
June 16, 2018 - New 2D Superresolution mode for ZEISS Airyscan offers higher resolution in live cell imaging
June 16, 2018 - Money Spurs Those With Heart Disease to Step Lively
June 16, 2018 - Lower Dose of Prostate Cancer Drug with Food
June 16, 2018 - New findings demonstrate how the food we eat affects biochemical signals in the gut
June 16, 2018 - Scientists develop method to determine metabolic activity of neural networks
June 16, 2018 - Topical gel may lower breast cancer risk in women with dense breast tissue
June 16, 2018 - Research team diagnoses asthma with nasal brush test
June 16, 2018 - Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations
June 16, 2018 - Novel PET imaging noninvasively pinpoints colitis inflammation
June 16, 2018 - New clinical trial of MS drug will be first to recognize needs of wheelchair users
June 16, 2018 - Evoke Announces FDA Submission of New Drug Application for Gimoti
June 16, 2018 - New study links gray hair with immune system activity and viral infection
June 16, 2018 - Various E-cigarette flavorings may increase risk of cardiovascular disease
June 16, 2018 - Research sheds light on pathways involved in transmitting itch sensations from skin to brain
June 16, 2018 - Eminent biologist resigns over allegations of gender discrimination and sexual harassment
June 16, 2018 - Consuming sugary soft drinks can make you fat
June 16, 2018 - CDC: Preterm Births Increased in United States During 2014-2016
June 16, 2018 - Adolescents with hay fever have higher rates of anxiety and depression, lower resistance to stress
June 16, 2018 - Metabolic process providing energy to heart muscle fails to mature in babies with hypertrophy
June 16, 2018 - TU Graz researchers manipulate enzymes to build ring-shaped molecular structures
June 16, 2018 - Looking Good! Plastic Surgery for Men Surges
June 16, 2018 - Discovery of how HIV hedges its bets opens the door to new therapies
June 15, 2018 - Researchers evaluate left ventricular systolic function after pulmonary valve replacement
June 15, 2018 - New resource launched based on first-hand experiences of premature baby loss
June 15, 2018 - About Teen Pregnancy | Teen Pregnancy | Reproductive Health
June 15, 2018 - In southern Mozambique, one out of three people diagnosed with HIV do not disclose their status
June 15, 2018 - Researchers discover genomic characteristics that define testicular germ cell cancer
June 15, 2018 - Engineers create first 3D computer model to show breast duct development
June 15, 2018 - ANU scientists invent new system that could help crack down on illegal drug trade
June 15, 2018 - Study shows remarkable plasticity of the brain in finding work-arounds after catastrophic injuries
June 15, 2018 - Study finds higher response to anti-PD1 immunotherapy in older melanoma patients
June 15, 2018 - New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
June 15, 2018 - Smoking, lack of exercise linked to early death after divorce
June 15, 2018 - Researchers identify gene enhancer that affects sex determination
June 15, 2018 - New collaboration integrates Intabio’s Blaze solution with Bruker’s mass spectrometers
June 15, 2018 - Blood samples can be used to uncover genetic secrets inside the brain
June 15, 2018 - Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
June 15, 2018 - Can you rely on the drugs that your doctor prescribes?
June 15, 2018 - WHO: Paraguay achieves malaria-free status
June 15, 2018 - Investigating Enamel Nanostructure with Nanoindentation
June 15, 2018 - FDA Approves Moxidectin for the Treatment of River Blindness
June 15, 2018 - Researchers discover cell structure that plays a role in epigenetic inheritance
June 15, 2018 - Study shows how using service dogs may provide physiological benefits to veterans with PTSD
June 15, 2018 - New chemical solution could reduce chances of infection associated with root canal work
June 15, 2018 - Fat and carb rich foods preferred by the brain
June 15, 2018 - Scientists discover unique feature in the ‘antennae’ of light-sensing neurons
June 15, 2018 - Researchers observe increase in activity of neurons grown on single layer of graphene
June 15, 2018 - Researchers find enzyme responsible for aircraft noise-related vascular damage
June 15, 2018 - Study shows improvements in adherence, outcomes of gout patients receiving text message reminders
June 15, 2018 - Accelerated brain maturation linked to stress in childhood
June 15, 2018 - FDA Alert: Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals
Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy

image_pdfDownload PDFimage_print

WALTHAM, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) — Tesaro, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Varubi (rolapitant) IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating.

About Varubi

Varubi is a highly selective and competitive antagonist of human substance P/neurokinin 1 (NK-1) receptors, which play an important role in the delayed phase of chemotherapy-induced nausea and vomiting (CINV). With a long plasma half-life of approximately seven days, a single dose of Varubi, as part of an antiemetic regimen, significantly improved complete response (CR) rates in the delayed phase of CINV. Results from three Phase 3 trials of Varubi oral tablets demonstrated a significant reduction in episodes of vomiting or use of rescue medication during the 25- to 120-hour period following administration of highly emetogenic and moderately emetogenic chemotherapy regimens. In addition, patients who received Varubi reported experiencing less nausea that interfered with normal daily life and fewer episodes of vomiting or retching over multiple cycles of chemotherapy. Results from a bioequivalence trial demonstrated comparability of the IV and oral formulations of Varubi.

Varubi IV is supplied in ready-to-use vials and does not require refrigerated storage or mixing. As a result, utilization in busy chemotherapy clinics is straightforward and easily adopted into existing practice patterns for administration of antiemetic regimens associated with emetogenic chemotherapy. Varubi IV is to be administered up to two hours before chemotherapy administration in combination with a 5-HT3 receptor antagonist and dexamethasone. No dosage adjustment is required for dexamethasone, a CYP3A4 substrate, and Varubi is the first intravenously administered NK-1 receptor antagonist approved by the FDA that does not contain polysorbate 80.

“The approval of Varubi IV represents a significant milestone for TESARO. The majority of NK-1 receptor antagonist doses are administered intravenously in the U.S., and with the introduction of Varubi IV, we now offer healthcare providers a unique, easy-to-use option that fits well into standard operating practices of a chemotherapy clinic or hospital,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO. “We will continue our efforts to expand awareness of delayed chemotherapy-induced nausea and vomiting, and plan to make this important medicine available next month.”

“Many healthcare providers tend to believe that CINV is no longer an unmet need but the reality is that more than half of patients treated with emetogenic chemotherapy experience delayed CINV, even when prescribed standard preventative therapies, such as a 5-HT3 receptor antagonist and dexamethasone,” said Lee Schwartzberg, M.D., Professor of Medicine at University of Tennessee Health Science Center. “The FDA approval of VARUBI IV gives doctors and nurses a new option to help protect their patients from these often preventable side effects.”

The full prescribing information for Varubi IV will be available at www.VarubiRx.com.

TOGETHER with TESARO™

TOGETHER with TESARO™ is a patient resource program dedicated to supporting people living with cancer. The program assists with access issues, so that patients with cancer can be free to focus on treatment goals and simply living life. It provides a full suite of services to meet each patient’s needs and individual experience. A team of access and affordability experts is available to help oncology practices and patients gain access to the medication they require. TOGETHER with TESARO will continue to evolve and grow to meet provider and patient needs.

For more information, please visit www.togetherwithtesaro.com or call 1-844-2TESARO (1-844-283-7276).

About Chemotherapy-Induced Nausea and Vomiting (CINV)

Chemotherapy-induced nausea and vomiting is a debilitating, yet often preventable side effect of chemotherapy. Up to 50% of patients undergoing highly or moderately emetogenic chemotherapy experience delayed CINV (25 to 120 hours post chemotherapy) — even when prescribed a 5-HT3 receptor antagonist and corticosteroid. Blocking both 5-HT3 and NK-1 receptors has been shown to offer better control of nausea and vomiting than inhibiting 5-HT3 receptors alone. Adding a single dose of Varubi to an antiemetic regimen, including a 5-HT3 receptor antagonist and corticosteroid, further improves prevention of CINV in the delayed phase following chemotherapy.

About the Varubi (Rolapitant) Clinical Program

The superior efficacy of Varubi was established in multiple global randomized, well-controlled, double-blinded clinical trials that enrolled more than 2,500 patients. Varubi, when administered in combination with a 5-HT3 receptor antagonist and dexamethasone, was superior to a 5-HT3 receptor antagonist and dexamethasone alone in preventing delayed CINV in patients receiving either moderately or highly emetogenic chemotherapy.

The clinical profile of Varubi in cisplatin-based highly emetogenic chemotherapy (HEC) was confirmed in two identical Phase 3 studies: HEC1 and HEC2. Both trials met their primary endpoint of complete response (CR), and demonstrated statistical superiority of rolapitant (180 mg oral) compared to active control (5-HT3 receptor antagonist plus dexamethasone) in the delayed phase (25–120 hours) of CINV. In HEC1, 264 patients received rolapitant and 262 received active control. The proportion of patients achieving a CR was 72.7% vs. 58.4% (p=<0.001). In HEC2, 271 patients received rolapitant and 273 received active control. The proportion of patients achieving a CR was 70.1% vs. 61.9% (p=0.043). The most common adverse reactions (≥3%) among patients receiving cisplatin-based chemotherapy were neutropenia (9% VARUBI vs. 8% control), hiccups (5% vs. 4%), and abdominal pain (3% vs. 2%).

A Phase 3 trial was also conducted to evaluate rolapitant (180 mg oral) compared to active control in 1,332 patients receiving moderately emetogenic chemotherapy regimens, including anthracycline/cyclophosphamide combinations, carboplatin, irinotecan, pemetrexed, oxaliplatin, and doxorubicin. This trial met its primary endpoint of CR, and demonstrated statistical superiority of rolapitant compared to active control (5-HT3 receptor antagonist plus dexamethasone) in the delayed phase of CINV. The proportion of patients achieving a CR was 71.3% vs 61.6% (p=<0.001). The most common adverse reactions (≥3%) among patients receiving these chemotherapies were decreased appetite (9% VARUBI vs. 7% control), neutropenia (7% vs. 6%), dizziness (6% vs. 4%), dyspepsia (4% vs. 2%), urinary tract infection (4% vs. 3%), stomatitis (4% vs. 2%), and anemia (3% vs. 2%).

Primary data from the three Phase 3 studies have been published in Lancet Oncology, the analysis of the non-AC MEC population was presented at the 2015 annual meeting of the Multinational Association for Supportive Care in Cancer, and commentary has been provided in Nature Reviews Clinical Oncology.

In addition to the Phase 3 program, a bioequivalence study was conducted in healthy volunteers to compare the exposure of the 166.5 milligram dose of IV rolapitant to the exposure of a 180 milligram dose of oral rolapitant. Study participants were randomized to receive a single dose of either 166.5 milligrams of intravenous rolapitant administered over 30 minutes (n=61) or 180 milligrams of oral rolapitant (n=62). The primary endpoint of this pivotal study was bioequivalence, defined by estimating whether the 90% confidence intervals (CI) for the ratio of the area under the curves (AUCs) of the two formulations are entirely included within the acceptance range of 80% to 125%. Safety and tolerability were also assessed for both formulations. The safety profile was consistent with previous clinical trials with oral rolapitant, except for infusion-site reactions observed with the IV formulation.

Varubi Additional Safety Information

Varubi is contraindicated in patients taking CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide. Varubi can significantly increase the plasma concentrations of thioridazine and pimozide, which may result in QT prolongation and Torsades de Pointes.

Varubi is a moderate inhibitor of CYP2D6 and significantly increases the plasma concentrations of CYP2D6 substrates for at least 28 days, with inhibitory effects expected to persist for an unknown duration. Monitor for adverse reactions when Varubi is coadministered with CYP2D6 substrates without a narrow therapeutic index (avoid coadministration with CYP2D6 substrates with a narrow therapeutic index, thioridazine and pimozide; see Contraindication).

In clinical trials, the most common adverse reactions reported were neutropenia, hiccups,
decreased appetite and dizziness. IV administration of VARUBI was also associated with infusion-related symptoms (e.g., sensation of warmth, abdominal pain, dizziness, and paresthesia).

Avoid use of Varubi in patients who require chronic administration of strong CYP3A4 inducers (e.g., rifampin), as significantly reduced plasma concentrations of Varubi can decrease the efficacy of Varubi.

Varubi, administered as an IV or oral medication, is not an inhibitor of CYP3A4 and no dose adjustment is required for co-administered CYP3A4 substrates, including dexamethasone.

Varubi IV did not inhibit breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). Varubi given as an oral dose is an inhibitor of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp). Increased plasma concentrations of BCRP substrates (e.g., methotrexate, topotecan, or irinotecan) and P-gp substrates (e.g., digoxin) with a narrow therapeutic index may result in potential adverse reactions. Monitor digoxin concentrations with concomitant use of Varubi, and adjust the dosage as needed to maintain therapeutic concentrations.

Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed, to maintain target INR.

Varubi is available by prescription only. Please see full prescribing information, including additional important safety information, available at www.varubirx.com.

About TESARO

TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the expected timing of the launch of Varubi IV in the United States. Forward-looking statements in this release involve substantial risks and uncertainties that could cause future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks related to manufacturing and supply, risks related to competition, and other matters that could affect the availability or commercial potential of Varubi IV. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO’s Annual Report on Form 10-K for the year ended December 31, 2016, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.

Source: TESARO, Inc.

Posted: October 2017

Related Articles:

Varubi (rolapitant) FDA Approval History

Tagged with:

About author

Related Articles